A study evaluating occurrence, risk factors and impact on long-term outcomes of severe infections in patients with steroid refractory acute -graft versus host disease treated with inolimomab or etanercept.

Trial Profile

A study evaluating occurrence, risk factors and impact on long-term outcomes of severe infections in patients with steroid refractory acute -graft versus host disease treated with inolimomab or etanercept.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Etanercept (Primary) ; Inolimomab (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Oct 2016 New trial record
    • 05 Sep 2016 Results published in the Bone Marrow Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top